Cite
HARVARD Citation
Sargeant, J. et al. (2022). The effects of empagliflozin, dietary energy restriction, or both on appetite‐regulatory gut peptides in individuals with type 2 diabetes and overweight or obesity: The SEESAW randomized, double‐blind, placebo‐controlled trial. Diabetes, obesity & metabolism. 24 (8), pp. 1509-1521. [Online].